Farshid Dayyani, MD, PhD, Discusses Multidisciplinary Approach to Research on Treatment for Gastroesophageal Adenocarcinoma

Farshid Dayyani, MD, PhD, of UC Irvine Health, spoke with CancerNetwork® about what multidisciplinary oncology professionals should know about a prospective, open-label, phase 2 trial (NCT04074343) examining the combination of cabozantinib (Cabometyx) with pembrolizumab (Keytruda) to overcome checkpoint inhibitor resistance for patients with metastatic or recurrent gastric and gastroesophageal adenocarcinoma.

Transcription:

The main early finding we had from this study is, because this is a single institution trial, that there’s a lot of interest. And we were getting a number of referrals from physicians in the community, from surgeons, and [from] gastroenterologists who hear about the study on clinicaltrials.gov or other sources and refer their patients to us. In that sense, we’ve been very fortunate to contribute to offering a new trial option to patients in Southern California and beyond. Actually, we have had patients from New York, as well.